A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.

Abstract:

:Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. The killing of leukemia cells is proportional to the radiation absorbed dose. We studied the feasibility and toxicity of escalating the doses of fractionated TBI above our previous prescription of 13.5 Gy. Sixteen evaluable patients with advanced hematologic malignancies were treated with twice daily TBI using a high-energy source (18-24 MV). The first patient cohort (n = 11) received a total dose of 14.4 Gy in nine fractions, and the second cohort (n = 5) received doses escalated to 15.3 Gy. All patients received high-dose etoposide (60 mg/kg) and allogeneic stem cell transplantation following the TBI. All patients had HLA-identical sibling donors. The median times for neutrophil and platelet engraftment were 13.5 and 12 days, respectively, and did not differ between the two cohorts. All but one patient developed treatment-related grade 3 or 4 mucositis. There were three cases of grade 4 pulmonary toxicity and three cases of grade 4 hepatic toxicity among the 14.4 Gy cohort, and one case each of grade 4 pulmonary and hepatic toxicities among the 15.3 Gy cohort. In most cases comorbid conditions contributed to these toxicities. Two patients had significant GVHD of the GI tract. Six relapses occurred, five (45%) in the 14.4 Gy cohort and one (20%) in the 15.3 Gy cohort. The 100-day treatment-related mortality rates were 9% and 20% for the 14.4 Gy and 15.3 Gy cohorts, respectively, and the median survivals were 226 and 201 days, respectively. We conclude that TBI dose escalation above the previously used 13.5 Gy dose is feasible using a high-energy source and high-dose etoposide. Acute and chronic toxicities were primarily related to GVHD, infection and relapse rather than to TBI.

journal_name

Bone Marrow Transplant

authors

Sobecks RM,Daugherty CK,Hallahan DE,Laport GF,Wagner ND,Larson RA

doi

10.1038/sj.bmt.1702230

subject

Has Abstract

pub_date

2000-04-01 00:00:00

pages

807-13

issue

8

eissn

0268-3369

issn

1476-5365

journal_volume

25

pub_type

杂志文章,多中心研究
  • Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.

    abstract::Repeated high-dose (HD) chemotherapy with peripheral blood stem cell (PBSC) transplantation is a new modality aimed at increasing both the dose and its intensity in the treatment of chemosensitive tumours. The aim of this study was to evaluate the tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of HD single...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702806

    authors: Vassal G,Tranchand B,Valteau-Couanet D,Mahé C,Couanet D,Schoeppfer C,Grill J,Kalifa C,Hill C,Ardiet C,Hartmann O

    更新日期:2001-03-01 00:00:00

  • 'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

    abstract::Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.223

    authors: Giaccone L,Mancini G,Mordini N,Gargiulo G,De Cecco V,Angelini S,Arpinati M,Baronciani D,Bozzoli V,Bramanti S,Calore E,Cavattoni IM,Cimminiello M,Colombo AA,Facchini L,Falcioni S,Faraci M,Fedele R,Guidi S,Iori AP,M

    更新日期:2018-01-01 00:00:00

  • Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.

    abstract::Antineoplastic therapy can be associated with drug-induced lung toxicity. With the increasing use of amiodarone for cardiac dysrhythmias there is an increasing possibility of its combined use with chemotherapies for various malignancies. We report a patient on long-term amiodarone who developed biopsy-proven drug-indu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703039

    authors: Bhagat R,Sporn TA,Long GD,Folz RJ

    更新日期:2001-05-01 00:00:00

  • Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant.

    abstract::The purpose of this study was to evaluate pre-transplant T-cell status in autologous hematopoietic progenitor-cell transplantation (HPCT) recipients. Between 1999 and 2002 we prospectively enrolled 85 autologous HPCT recipients with solid tumors (N = 50) or hematological malignancies (n = 35). Patient diagnoses includ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705073

    authors: Rosinski SL,McNiece IK,Shpall EJ,Clough N,Russell P,Blunk B,Nieto Y

    更新日期:2005-09-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract::In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.193

    authors: Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期:2014-12-01 00:00:00

  • Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.

    abstract::A cohort of 138 children with 144 hematopoietic stem cell transplantation (HSCT) performed in 1997-2006 were analyzed to evaluate risk factors and mortality predictors of hepatic veno-occlusive disease (VOD). Nineteen patients (13.2%) developed VOD (nine boys, median age 3.5 years) at 1-21 days after HSCT (median 13 d...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705835

    authors: Cheuk DK,Wang P,Lee TL,Chiang AK,Ha SY,Lau YL,Chan GC

    更新日期:2007-11-01 00:00:00

  • Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation.

    abstract::Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other immunosuppressive regimens is asso...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705877

    authors: Bashoura L,Gupta S,Jain A,Couriel DR,Komanduri KV,Eapen GA,Safdar A,Broglio KR,Adachi R,Dickey BF

    更新日期:2008-01-01 00:00:00

  • Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD.

    abstract::Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation. Pretransplant conditioning regimes cause release of proinflammatory cytokines that stimulate alloreactive donor T cells to attack recipient tissues. IL-10 has been shown to directly downregulate CD4+ T cells...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705218

    authors: Weston LE,Geczy AF,Briscoe H

    更新日期:2006-01-01 00:00:00

  • Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease.

    abstract::HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0145-1

    authors: Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

    更新日期:2018-09-01 00:00:00

  • Successful treatment of parvovirus B19 infection and red cell aplasia occurring after an allogeneic bone marrow transplant.

    abstract::Chronic parvovirus B19 infection in the immunocompromised host may cause severe anaemia secondary to failure of erythropoiesis. This has been previously documented in patients with the Acquired Immune Deficiency Syndrome (AIDS), congenital immunodeficiencies and in children with acute lymphoblastic leukaemia during ma...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Corbett TJ,Saw H,Popat U,MacMahon E,Cohen BJ,Knowles WA,Beard S,Prentice HG

    更新日期:1995-11-01 00:00:00

  • Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation.

    abstract::Community-acquired respiratory virus (RV) infections are an important cause of disease in immunocompromised adults with cancer. To investigate the viral etiology, incidence, clinical presentation, and outcome of RV infections in an outpatient cohort of adult bone marrow or peripheral blood stem cell transplant (SCT) r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704257

    authors: Roghmann M,Ball K,Erdman D,Lovchik J,Anderson LJ,Edelman R

    更新日期:2003-12-01 00:00:00

  • Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor.

    abstract::The aim was to evaluate two transplant strategies for patients who lack HLA-identical donors, namely HLA-A, HLA-B or -DR beta 1 mismatched unrelated donor (MM URD) transplants (n=14) and umbilical cord blood transplants (UCB, n=27). Diagnosis, disease stage and age were similar in the two groups. Cell dose was lower i...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2008.239

    authors: Ringdén O,Okas M,Uhlin M,Uzunel M,Remberger M,Mattsson J

    更新日期:2008-11-01 00:00:00

  • Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.

    abstract::Twenty-five patients with hematologic malignancies (n = 21) or aplastic anemia (n = 4) undergoing an allogeneic BMT from an HLA-identical sibling developed cytomegalovirus (CMV) antigenemia at a mean interval from BMT of 41 days (range 16-141 days). All patients were treated at the time of antigenemia in the absence o...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bacigalupo A,van Lint MT,Tedone E,Moro F,Sanna MA,Longren M,Trespi G,Frassoni F,Occhini D,Gualandi F

    更新日期:1994-06-01 00:00:00

  • Bone marrow transplantation in sickle cell disease: the Belgian experience.

    abstract::Twenty eight patients underwent bone marrow transplantation (BMT) for sickle cell anemia in Belgium. The patients were originating from Central Africa, were young and symptomatic. Engraftment occurred in all patients and was sustained in 25. In 3 patients, a bone marrow rejection was observed. One of these patients un...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Vermylen C,Cornu G,Ferster A,Ninane J,Sariban E

    更新日期:1993-01-01 00:00:00

  • Unusual recurrence of chronic myelogenous leukemia following bone marrow transplantation.

    abstract::We report a patient who developed a bone and adjacent soft tissue malignancy 22 months after bone marrow transplantation (BMT) for Philadelphia chromosome positive chronic myelogenous leukemia (CML). Concomitant bone marrow was cytologically and cytogenetically normal. Cytogenetic study of tumoral tissue was unsuccess...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Millot F,Facon T,Kerckaert JP,Fenaux P,Lai JL,Parent M,Bauters F,Jouet JP

    更新日期:1991-05-01 00:00:00

  • Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children.

    abstract::Eight children underwent reduced-intensity stem cell transplantation (RIST) from an HLA-matched sibling. They received a fludarabine-melphalan based preparative regimen. Stem cell source was bone marrow, and GVHD prophylaxis consisted of cyclosporine A alone. Acute GVHD grade II-IV and grade III-IV were observed in fo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705285

    authors: Inoue M,Okamura T,Yasui M,Sawada A,Sakata N,Koyama M,Sakata A,Takeshita Y,Kouroki M,Yagi K,Kawa K

    更新日期:2006-03-01 00:00:00

  • Effects of ICOSLG expressed in mouse hematological neoplasm cell lines in the GVL reaction.

    abstract::As a member of the B7 family, inducible co-stimulator ligand (ICOSLG) expressed on tumor cell has been reported to have an important role in tumor immunity. In this study, we sought to determine whether the expression of ICOSLG in mouse hematological malignancy cells influences GVL reaction after mouse allogeneic BMT....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.103

    authors: Wang B,Ma N,Cheng H,Zhou H,Qiu H,Yang J,Wang J

    更新日期:2013-01-01 00:00:00

  • Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.

    abstract::We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

    更新日期:1994-10-01 00:00:00

  • Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation.

    abstract::Short stature is characteristic of Hurler syndrome, or mucopolysaccharidosis type IH (MPS IH). Hematopoietic stem cell transplantation (HSCT) is used to treat children with MPS IH. While HSCT corrects some of the metabolic features of MPS IH, its effects on growth are not well delineated. We investigated growth in pat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.20

    authors: Polgreen LE,Tolar J,Plog M,Himes JH,Orchard PJ,Whitley CB,Miller BS,Petryk A

    更新日期:2008-06-01 00:00:00

  • IL-21 is critical for GVHD in a mouse model.

    abstract::Immunological effects of IL-21 on T, B and natural killer (NK) cells have been reported, but the role of IL-21 in GVHD remains obscure. Here, we demonstrate that morbidity and mortality of GVHD was significantly reduced after BMT with splenocytes from IL-21R(-/-) mice compared with those from wild type mice. To furthe...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.223

    authors: Meguro A,Ozaki K,Oh I,Hatanaka K,Matsu H,Tatara R,Sato K,Leonard WJ,Ozawa K

    更新日期:2010-04-01 00:00:00

  • Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation.

    abstract::Infection with human cytomegalovirus (HCMV) after allogeneic bone marrow transplantation (BMT) was studied in 12 HCMV seronegative recipients of marrow from seropositive donors by weekly monitoring of cultures, expression of HCMV antigenemia (pp65) in granulocytes, polymerase chain reaction (PCR) on HCMV-DNA in granul...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: de Gast GC,Boland GJ,Vlieger AM,de Weger RA,Verdonck LF,Zwaan FE,Jiwa NM

    更新日期:1992-04-01 00:00:00

  • Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature.

    abstract::Myasthenia gravis (MG) is a rare complication of allogeneic bone marrow transplantation (BMT). We present the 11th case in the medical literature, a 23-year-old female 100 months post-allogeneic bone marrow transplantation for acute myelogenous leukemia (AML). After discontinuation of immunosuppression for chronic gra...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700759

    authors: Mackey JR,Desai S,Larratt L,Cwik V,Nabholtz JM

    更新日期:1997-05-01 00:00:00

  • Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation.

    abstract::Children receiving a bone marrow transplant (BMT) are at risk for neuropsychological late effects because of potentially neurotoxic chemotherapy and total body irradiation. The goal of this study was to prospectively and longitudinally assess the intellectual and adaptive functioning of children receiving a BMT. This ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700699

    authors: Kramer JH,Crittenden MR,DeSantes K,Cowan MJ

    更新日期:1997-03-01 00:00:00

  • Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.

    abstract::There is substantial progress in preventing and treating cytomegalovirus (CMV) infections and CMV-related disease after allogeneic bone marrow transplantation. In CMV-seronegative recipients, use of CMV-seronegative blood products eliminates most CMV infections. Effective prophylaxis for CMV-seropositive recipients is...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Winston DJ,Gale RP

    更新日期:1991-07-01 00:00:00

  • Long-term oral complications of allogeneic haematopoietic SCT.

    abstract::This study assessed the incidence of long-term oral complications in 88 survivors of allogeneic haematopoietic cell transplantation (HCT). Patients examined were between 6 months and 6 years post-HCT and aged from 19 to 65 years. Subjects were investigated for both the subjective and objective features of long-term ad...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.63

    authors: Hull KM,Kerridge I,Schifter M

    更新日期:2012-02-01 00:00:00

  • Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?

    abstract::The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703255

    authors: Sweetenham JW

    更新日期:2001-11-01 00:00:00

  • The recovery of resistance to alloengraftment following lethal irradiation and administration of T cell-depleted syngeneic bone marrow.

    abstract::Recent studies from this laboratory have shown that unmanipulated, MHC-mismatched allogeneic bone marrow (BM) engrafts and produces complete allogeneic chimerism when administered to recipient mice 8 days following lethal irradiation and reconstitution with T cell-depleted (TCD) syngeneic bone marrow. Host lymphopoiet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chester CH,Sykes M,Sachs DH

    更新日期:1989-03-01 00:00:00

  • Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.

    abstract::Thirty patients with relapsed pediatric solid tumors received high-dose carboplatin and etoposide with autologous marrow support in a dose-escalation trial. These patients had received extensive prior treatment, which included both cisplatin and etoposide in 25 cases. Six patient cohorts received carboplatin in doses ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Santana VM,Schell MJ,Williams R,Bowman LC,Thompson EI,Brenner MK,Mirro J Jr

    更新日期:1992-11-01 00:00:00

  • Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation.

    abstract::This study evaluated whether cytokine-induced blood stem cell mobilization also mobilized lymphoma cells and whether lymphoma cell mobilization affected outcome post autologous blood stem cell transplant. Blood stem cell collections from 26 non-Hodgkin's lymphoma (NHL) patients harvested during steady-state (non-mobil...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703124

    authors: Demirkazik A,Kessinger A,Armitage JO,Bierman PJ,Lynch J,Vose J,Chan W,Sharp JG

    更新日期:2001-07-01 00:00:00

  • Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD).

    abstract::A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally for 7 days, and 15 patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705621

    authors: Agha-Hosseini F,Mirzaii-Dizgah I,Ghavamzadeh L,Ghavamzadeh A,Tohidast-Acrad Z

    更新日期:2007-04-01 00:00:00